1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  

This page is powered by Blogger. Isn't yours?

Saturday, March 25, 2017

 

Focused Ultrasound Trialed for Alzheimer's Disease






























Image Source: GIGAMEN

Aim is to modulate blood-brain barrier to make anti-amyloid drugs more effective

Researchers have successfully used focused beams of ultrasound to open the blood-brain barrier in patients with Alzheimer's disease, the first step in a study to see whether the technology can facilitate ablation of beta-amyloid plaques associated with the illness.

The aim is to make the blood-brain barrier more permeable so as to help amyloid-scavenging drugs such as antibodies reach the plaques.

"We treated the first two Alzheimer's patients yesterday, and things went well. We were able to open the blood-brain barrier successfully," the study's principal investigator, Nir Lipsman, MD, PhD, a neurosurgeon at Sunnybrook Health Sciences Centre in Toronto, said in an email Friday. "Both are doing well so far."

This is the first such use in humans of focused ultrasound to treat Alzheimer's disease, Lipsman said in an interview. The main objective of this phase I trial is to show that the technique is safe.

"If it is safe and technically feasible, subsequent study would combine focused ultrasound with an [anti-amyloid] agent that has trouble crossing the blood-brain barrier," he said. He cited a study in Nature last August that showed in mice that anti-amyloid antibodies can reduce amyloid and stabilize cognitive deficits. "Question is whether enhancing antibody delivery can improve on these results," he said in an email.

Alzheimer specialists not involved in the study were divided over whether this is an appropriate time to begin trials with humans, or whether more work should be done in animals first.

Samuel Gandy, MD, PhD, of Mount Sinai Hospital in New York City, said in an email that while focused ultrasound has been shown to be helpful in treating essential tremor, "brain regions involved in cognition, especially brain regions like the hippocampus that are performing poorly, may not tolerate the insult so well."


Such techniques are better at silencing overactive brain regions than improving function, he said. And he suggested that before moving to human trials, the technique should have been tested in dogs with an Alzheimer's-like condition called CCD (canine cognitive disorder) or in aged nonhuman primates.

Steven DeKosky, MD, of the University of Florida who has worked with Lipsman in the past, disagreed. "I don't think it's premature from the standpoint of the science," he said. Focused ultrasound has been approved for use in the treatment of essential tremor, he said, so "we know the technique can be used in humans safely." He described Lipsman's study as an "extraordinary clever" method of getting anti-Alzheimer medications to their target in the brain.

One concern is whether amyloid plaques could be removed in enough areas of the brain to affect symptoms. "The biggest problem is the cortex is big and the area of focus is small," he said.

David Knopman, MD, of the Mayo Clinic in Rochester, Minn., said he was not familiar with the Lipsman study, but he expressed similar reservations about human trials. Before studies are done in humans, he said, "there should be a clear understanding of what the target is and what the relationship is between the therapeutic target and the desired outcome -- which would be cognitive improvement or cognitive stability."

In this case, he pointed out, the target -- the amyloid plaques -- might have no relationship to the desired outcome.

Lipsman said his study "is the culmination of a few decades of research in animals," including some 200 studies on blood-brain barrier opening with focused ultrasound. "We felt it had reached the threshold where a phase I study was justified."

The study raises two important questions. One is whether it makes sense to go after amyloid when there are questions about the link between amyloid and Alzheimer's disease.

The so-called amyloid hypothesis in Alzheimer's has suffered a series blows in recent clinical trials of anti-amyloid drugs -- none of which have made any impact on cognition in patients with definitely Alzheimer's disease -- but opinion is divided over whether or not it should be abandoned. If the amyloid hypothesis is discarded, Lipsman's study would need to be re-evaluated.

"The amyloid hypothesis has more data by far than any other hypothesis," said DeKosky. "The problem is that there isn't any other hypothesis." Amyloid can appear in the brain years before patients begin showing symptoms. On the other hand, genetic studies have linked mutations in amyloid to Alzheimer's disease symptoms. And the failure of anti-amyloid drugs might simply mean "we have the wrong dose or the wrong drug."

The other question about Lipsman's study concerns the role of the Focused Ultrasound Foundation, based in Charlottesville, Va., which is dedicated to expanding uses of the technology. The group aggressively promotes the use of focused ultrasound for some 80 conditions, including Alzheimer's disease, Parkinson's disease, uterine fibroids, atrial fibrillation, congestive heart failure, depression, diabetes, obesity, cancers of the prostate, kidneys, pancreas, bladder, breast and dozens more illnesses, most at early stages of development.

The foundation is supporting Lipsman's phase I trial, which will include six patients. In the U.S., focused ultrasound has been approved by the FDA for essential tremor, uterine fibroids, pain from bone metastases, and ablation of prostate tissue in cancer or BPH, the foundation says.

Story Source: The above story is based on materials provided by MEDPAGETODAY
Note: Materials may be edited for content and length
Click here to read original article